Publications

Lourenco ARita, Ban Y, Crowley MJ, Lee SB, Ramchandani D, Du W, Elemento O, George JT, Jolly MKumar, Levine H et al..  2020.  Differential Contributions of Pre- and Post-EMT Tumor Cells in Breast Cancer Metastasis.. Cancer Res. 80(2):163-169.

Durrans A, Gao D, Gupta R, Fischer KR, Choi H, Rayes TEl, Ryu S, Nasar A, Spinelli CF, Andrews W et al..  2015.  Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC.. PLoS One. 10(6):e0129123.

Markowitz GJ, Havel LS, Crowley MJp, Ban Y, Lee SB, Thalappillil JS, Narula N, Bhinder B, Elemento O, Wong STc et al..  2018.  Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.. JCI Insight. 3(13)

Chaudhri VK, Salzler GG, Dick SA, Buckman MS, Sordella R, Karoly ED, Mohney R, Stiles BM, Elemento O, Altorki NK et al..  2013.  Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor.. Mol Cancer Res. 11(6):579-92.

Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB et al..  2021.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. Lancet Oncol. 22(6):824-835.

Choi H, Sheng J, Gao D, Li F, Durrans A, Ryu S, Lee SB, Narula N, Rafii S, Elemento O et al..  2015.  Transcriptome analysis of individual stromal cell populations identifies stroma-tumor crosstalk in mouse lung cancer model.. Cell Rep. 10(7):1187-201.